HomeCompareSEEL vs NOBL

SEEL vs NOBL: Dividend Comparison 2026

SEEL yields 540.54% · NOBL yields 2.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SEEL wins by $112786.20M in total portfolio value
10 years
SEEL
SEEL
● Live price
540.54%
Share price
$0.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112786.22M
Annual income
$82,692,515,806.61
Full SEEL calculator →
NOBL
NOBL
● Live price
2.17%
Share price
$104.67
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.9K
Annual income
$249.78
Full NOBL calculator →

Portfolio growth — SEEL vs NOBL

📍 SEEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSEELNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SEEL + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SEEL pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SEEL
Annual income on $10K today (after 15% tax)
$45,945.95/yr
After 10yr DRIP, annual income (after tax)
$70,288,638,435.62/yr
NOBL
Annual income on $10K today (after 15% tax)
$184.52/yr
After 10yr DRIP, annual income (after tax)
$212.31/yr
At 15% tax rate, SEEL beats the other by $70,288,638,223.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SEEL + NOBL for your $10,000?

SEEL: 50%NOBL: 50%
100% NOBL50/50100% SEEL
Portfolio after 10yr
$56393.12M
Annual income
$41,346,258,028.20/yr
Blended yield
73.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SEEL right now

SEEL
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
-156.6
Piotroski
5/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SEEL buys
0
NOBL buys
0
No recent congressional trades found for SEEL or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSEELNOBL
Forward yield540.54%2.17%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$112786.22M$22.9K
Annual income after 10y$82,692,515,806.61$249.78
Total dividends collected$110217.05M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SEEL vs NOBL ($10,000, DRIP)

YearSEEL PortfolioSEEL Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$64,754$54,054.05$10,917$217.08+$53.8KSEEL
2$396,410$327,123.28$11,903$221.48+$384.5KSEEL
3$2,295,726$1,871,567.31$12,962$225.68+$2.28MSEEL
4$12,586,137$10,129,710.14$14,099$229.68+$12.57MSEEL
5$65,369,349$51,902,182.37$15,319$233.49+$65.35MSEEL
6$321,877,325$251,932,121.38$16,628$237.10+$321.86MSEEL
7$1,503,762,535$1,159,353,797.14$18,033$240.53+$1503.74MSEEL
8$6,671,013,644$5,061,987,731.83$19,539$243.78+$6670.99MSEEL
9$28,124,961,234$20,986,976,635.20$21,154$246.86+$28124.94MSEEL
10$112,786,224,327$82,692,515,806.61$22,884$249.78+$112786.20MSEEL

SEEL vs NOBL: Complete Analysis 2026

SEELStock

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full SEEL Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this SEEL vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SEEL vs SCHDSEEL vs JEPISEEL vs OSEEL vs KOSEEL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.